117 related articles for article (PubMed ID: 19204160)
1. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50.
Bove R; Musallam A; Healy BC; Houtchens M; Glanz BI; Khoury S; Guttmann CR; De Jager PL; Chitnis T
BMC Neurol; 2013 Jul; 13():73. PubMed ID: 23822612
[TBL] [Abstract][Full Text] [Related]
2. Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
Mattiesing RM; Kramer E; Strijbis EM; Brouwer I; van Schijndel RA; Gentile G; Battaglini M; De Stefano N; Uitdehaag BM; Barkhof F; Vrenken H; Schoonheim MM
Mult Scler; 2024 Jan; 30(1):44-54. PubMed ID: 38018502
[TBL] [Abstract][Full Text] [Related]
3. Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II study.
Bsteh G; Ehling R; Walchhofer LM; Hegen H; Auer M; Wurth S; Di Pauli F; Wagner M; Reindl M; Deisenhammer F; Berger T
PLoS One; 2017; 12(7):e0181458. PubMed ID: 28749974
[TBL] [Abstract][Full Text] [Related]
4. A Genetic Risk Variant for Multiple Sclerosis Severity is Associated with Brain Atrophy.
Gasperi C; Wiltgen T; McGinnis J; Cerri S; Moridi T; Ouellette R; Pukaj A; Voon C; Bafligil C; Lauerer M; Andlauer TFM; Held F; Aly L; Shchetynsky K; Stridh P; Harroud A; Wiestler B; Kirschke JS; Zimmer C; Baras A; Piehl F; Berthele A; Granberg T; Kockum I; Hemmer B; Mühlau M
Ann Neurol; 2023 Dec; 94(6):1080-1085. PubMed ID: 37753809
[TBL] [Abstract][Full Text] [Related]
5. Disease Progression in Multiple System Atrophy: The Value of Clinical Cohorts with Long Follow-Up.
Saulnier T; Fabbri M; Pavy-Le Traon A; Le Goff M; Helmer C; Péran P; Meissner WG; Rascol O; Foubert-Samier A; Proust-Lima C
Mov Disord; 2023 Aug; 38(8):1567-1569. PubMed ID: 37565400
[No Abstract] [Full Text] [Related]
6. Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.
Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Ramasamy DP; Hojnacki D; Lizarraga AA; Kolb C; Eckert S; Weinstock-Guttman B; Zivadinov R
AJNR Am J Neuroradiol; 2020 Sep; 41(9):1577-1583. PubMed ID: 32763899
[TBL] [Abstract][Full Text] [Related]
7. Body mass index, but not vitamin D status, is associated with brain volume change in MS.
Mowry EM; Azevedo CJ; McCulloch CE; Okuda DT; Lincoln RR; Waubant E; Hauser SL; Pelletier D
Neurology; 2018 Dec; 91(24):e2256-e2264. PubMed ID: 30429274
[TBL] [Abstract][Full Text] [Related]
8. Impaired Cerebral Perfusion in Multiple Sclerosis: Relevance of Endothelial Factors.
Monti L; Morbidelli L; Rossi A
Biomark Insights; 2018; 13():1177271918774800. PubMed ID: 29795976
[TBL] [Abstract][Full Text] [Related]
9. Exploration of machine learning techniques in predicting multiple sclerosis disease course.
Zhao Y; Healy BC; Rotstein D; Guttmann CR; Bakshi R; Weiner HL; Brodley CE; Chitnis T
PLoS One; 2017; 12(4):e0174866. PubMed ID: 28379999
[TBL] [Abstract][Full Text] [Related]
10. Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis.
Cramer SP; Modvig S; Simonsen HJ; Frederiksen JL; Larsson HB
Brain; 2015 Sep; 138(Pt 9):2571-83. PubMed ID: 26187333
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Waubant E; Maghzi AH; Revirajan N; Spain R; Julian L; Mowry EM; Marcus J; Liu S; Jin C; Green A; McCulloch CE; Pelletier D
Ann Clin Transl Neurol; 2014 May; 1(5):340-7. PubMed ID: 25356404
[TBL] [Abstract][Full Text] [Related]
12. Determinants of disability in multiple sclerosis: an immunological and MRI study.
Tortorella P; Laganà MM; Saresella M; Tavazzi E; Preti MG; Ricci C; Baglio F; Marventano I; Piancone F; Baselli G; Cecconi P; Caputo D; Clerici M; Rovaris M
Biomed Res Int; 2014; 2014():875768. PubMed ID: 24818159
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of brain volume measures in multiple sclerosis.
De Stefano N; Airas L; Grigoriadis N; Mattle HP; O'Riordan J; Oreja-Guevara C; Sellebjerg F; Stankoff B; Walczak A; Wiendl H; Kieseier BC
CNS Drugs; 2014 Feb; 28(2):147-56. PubMed ID: 24446248
[TBL] [Abstract][Full Text] [Related]
14. Benign multiple sclerosis: does it exist?
Correale J; Ysrraelit MC; Fiol MP
Curr Neurol Neurosci Rep; 2012 Oct; 12(5):601-9. PubMed ID: 22777531
[TBL] [Abstract][Full Text] [Related]
15. Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.
Galetta KM; Graves J; Talman LS; Lile DJ; Frohman EM; Calabresi PA; Galetta SL; Balcer LJ
J Neuroophthalmol; 2012 Jun; 32(2):116-23. PubMed ID: 22269944
[TBL] [Abstract][Full Text] [Related]
16. White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.
Cambron M; D'Haeseleer M; Laureys G; Clinckers R; Debruyne J; De Keyser J
J Cereb Blood Flow Metab; 2012 Mar; 32(3):413-24. PubMed ID: 22214904
[TBL] [Abstract][Full Text] [Related]
17. Rate of brain atrophy in benign vs early multiple sclerosis.
Gauthier SA; Berger AM; Liptak Z; Duan Y; Egorova S; Buckle GJ; Glanz BI; Khoury SJ; Bakshi R; Weiner HL; Guttmann CR
Arch Neurol; 2009 Feb; 66(2):234-7. PubMed ID: 19204160
[TBL] [Abstract][Full Text] [Related]
18. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
19. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis.
Gordon-Lipkin E; Chodkowski B; Reich DS; Smith SA; Pulicken M; Balcer LJ; Frohman EM; Cutter G; Calabresi PA
Neurology; 2007 Oct; 69(16):1603-9. PubMed ID: 17938370
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
